HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

P C Limburg Selected Research

Myeloblastin (Proteinase 3)

5/2009Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils.
11/2003Membrane proteinase 3 expression on resting neutrophils as a pathogenic factor in PR3-ANCA-associated vasculitis.
9/2002Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis.
7/2002In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase.
6/2002Expression of recombinant proteinase 3, the autoantigen in Wegener's granulomatosis, in insect cells.
1/2001Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: epitope analysis using synthetic peptides.
12/2000In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG).
10/2000Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies.
9/2000Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


P C Limburg Research Topics

Disease

10Systemic Lupus Erythematosus (Libman-Sacks Disease)
05/2013 - 12/2000
10Wegener Granulomatosis (Wegener's Granulomatosis)
05/2009 - 03/2000
6Rheumatoid Arthritis
05/2009 - 12/2000
5Vasculitis (Vasculitides)
11/2014 - 03/2000
5Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
11/2014 - 07/2002
5Inflammation
05/2013 - 11/2003
3Glomerulonephritis
11/2014 - 03/2000
2Proteinuria
11/2014 - 01/2002
2Systemic Vasculitis
10/2012 - 05/2009
2Necrosis
08/2010 - 07/2006
2Autoimmune Diseases (Autoimmune Disease)
08/2010 - 01/2006
2Neoplasm Metastasis (Metastasis)
11/2004 - 03/2001
2Acute-Phase Reaction
11/2004 - 07/2004
2Neoplasms (Cancer)
06/2001 - 02/2000
1Nephritis
11/2014
1Atherosclerotic Plaque (Atheroma)
10/2012
1Vascular Diseases (Vascular Disease)
10/2012
1Ischemia
10/2012
1Acute Coronary Syndrome
10/2012
1Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)
10/2012
1Atherosclerosis
10/2012
1Stroke (Strokes)
10/2012
1Amyloidosis
06/2011
1Ankylosing Spondylitis
09/2010
1Buruli Ulcer
12/2007
1Hepatocellular Carcinoma (Hepatoma)
07/2006
1Sepsis (Septicemia)
07/2004
1Breast Neoplasms (Breast Cancer)
07/2004
1Tourette Syndrome (Tourette's Syndrome)
04/2004
1Lupus Nephritis
01/2002
1Constipation
01/2002
1Tic Disorders (Tic Disorder)
04/2001
1Myeloid Leukemia (Leukemia, Myelocytic)
02/2001
1Thyroid Diseases (Thyroid Disease)
02/2001
1Left Ventricular Dysfunction
06/2000
1Renal Cell Carcinoma (Grawitz Tumor)
06/2000
1Cholestasis
05/2000
1Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
05/2000
1Autoimmune Hepatitis
05/2000
1Liver Diseases (Liver Disease)
05/2000
1Bacterial Infections (Bacterial Infection)
02/2000

Drug/Important Bio-Agent (IBA)

14Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
11/2014 - 05/2000
9Myeloblastin (Proteinase 3)IBA
05/2009 - 09/2000
7AutoantibodiesIBA
09/2010 - 10/2000
5AntibodiesIBA
09/2010 - 08/2001
5C-Reactive ProteinIBA
11/2004 - 02/2000
5Peroxidase (Myeloperoxidase)IBA
11/2003 - 09/2000
4HMGB1 Protein (HMG1)IBA
11/2014 - 08/2010
4Acute-Phase Proteins (Acute-Phase Protein)IBA
07/2006 - 02/2000
4Interleukin-6 (Interleukin 6)IBA
07/2004 - 02/2000
4AntigensIBA
02/2001 - 03/2000
3Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
11/2004 - 03/2001
2Protein Kinases (Protein Kinase)IBA
08/2006 - 07/2006
2p38 Mitogen-Activated Protein KinasesIBA
08/2006 - 07/2006
2Matrix Metalloproteinase 3 (Stromelysin 1)IBA
07/2003 - 12/2000
2Immunoglobulin G (IgG)IBA
01/2002 - 12/2000
2Serum Amyloid A Protein (Serum Amyloid A)IBA
03/2001 - 02/2000
2PeptidesIBA
01/2001 - 12/2000
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
11/2014
1CreatinineIBA
11/2014
1Nuclear Proteins (Protein, Nuclear)IBA
10/2012
1Prealbumin (Transthyretin)IBA
06/2011
1Toll-Like Receptors (Toll-Like Receptor)IBA
08/2010
1ChromatinIBA
08/2010
1advanced glycosylation end-product receptorIBA
08/2010
1Histones (Histone)IBA
08/2010
1DNA-Binding Proteins (DNA Binding Protein)IBA
08/2010
1Transcription Factors (Transcription Factor)IBA
11/2009
1Interferon-gamma (Interferon, gamma)IBA
12/2007
1Fibrinogen (Factor I)FDA Link
07/2006
1Messenger RNA (mRNA)IBA
07/2006
1InterleukinsIBA
07/2006
1Complement System Proteins (Complement)IBA
01/2006
1Opsonin Proteins (Opsonins)IBA
12/2005
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2004
1Serum Amyloid P-ComponentIBA
07/2004
1Immunologic Factors (Immunomodulators)IBA
04/2004
1glucuronyl glucosamine glycan sulfate (Vessel)IBA
11/2003
1mycophenolate mofetil (Cellcept)FDA LinkGeneric
06/2003
1DNA (Deoxyribonucleic Acid)IBA
06/2003
1AutoantigensIBA
07/2002
1CytokinesIBA
07/2002
1Amyloid (Amyloid Fibrils)IBA
01/2002
1Recombinant ProteinsIBA
08/2001
1Immunoglobulin M (IgM)IBA
04/2001
1Insulin-Like Growth Factor I (IGF-1)IBA
03/2001
1thyroid microsomal antibodies (TMII)IBA
02/2001
1Antigen-Antibody Complex (Immune Complex)IBA
12/2000
1Fc Receptors (Fc Receptor)IBA
12/2000
1Interleukin-2 (IL2)IBA
06/2000
1Primary sclerosing cholangitisIBA
05/2000
1Acid PhosphataseIBA
03/2000
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2000

Therapy/Procedure

2Hepatectomy
11/2004 - 03/2001
1Laparotomy
11/2004
1Cryosurgery
03/2001
1Immunotherapy
02/2001
1Aftercare (After-Treatment)
06/2000